Pirlimycin Struktur

Pirlimycin

Bezeichnung:Pirlimycin

CAS-Nr79548-73-5

Englisch Name:Pirlimycin

CBNumberCB7947410

SummenformelC17H31ClN2O5S

Molgewicht410.96

MOL-Datei79548-73-5.mol

Pirlimycin physikalisch-chemischer Eigenschaften

Siedepunkt	643.9±55.0 °C(Predicted)
Dichte	1.31
storage temp.	Store at -20°C
Löslichkeit	Soluble in ethanol;Soluble in methanol;Soluble in DMSO;Soluble in dimethyl formamide
Aggregatzustand	solid
pka	12.88±0.70(Predicted)
Stabilität	Hygroscopic

Pirlimycin Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
Pirlimycin is a semi-synthetic lincosamide prepared from clindamycin by hydrolysing the propyl N-methylproline and re-annealing a 4-ethylpipecolic acid. Pirlimycin is more hydrophobic than clindamycin and is more potent against a number of important pathogens. Like other members of the lincosamide family, pirlimycin is a broad spectrum antibiotic with activity against anaerobic bacteria and protozoans. Pirlimycin acts by binding to the 23S ribosomal subunit, blocking protein synthesis. Pirlimycin has been less extensively researched than the older lincosamides.
Biologische Aktivität
pirlimycin, a lincosamide antibiotic, is effective against gram-positive bacteria, including staphylococcus, bacteroides, streptococcus, and plasmodium. it functions via inhibiting protein synthesis in bacteria by inducing premature dissociation of the peptidyl-trna from the ribosome.
Veterinary Drugs and Treatments
Pirlimycin mastitis tubes are indicated for the treatment of clinical and subclinical mastitis caused by susceptible organisms in lactating dairy cattle.
in vitro
pirlimycin showed activity against helicobacter pylori with a minimal inhibitory concentration [mic] 50 of 4 μg/ml and an mic90 of 64 μg/ml [1].
in vivo
cows were treated with 50 mg of pirlimycin via two intramammary infusions per quarter at a 24-hour interval (2-day) for 2, 5, or 8 days. pirlimycin showed antibiotic therapy against environmental streptococcus spp and staphylococcus aureus intramammary individual and combined infections [1]. specifically, pirlimycin cured environmental streptococcus spp infections in 66.7% (14/21), 85% (17/20), 100% (14/14) in the 2-day group, 5-day group and 8-day group, respectively. s. aureus infections were cured by the treatment of pirlimycin in 13.3% (2/15), 31.3% (5/16), 83.3% (5/6) in the 2-day group, 5-day group and 8-day group, respectively. furthermore, s. aureus, s. dysgalactiae subsp dysgalactiae, and enterococcus spp intramammary infections were eliminated by the extended treatment of pirlimycin in 8-day group [2].
Einzelnachweise
[1]. westblom, t., midkiff, b., & czinn, s. in vitro susceptibility ofhelicobacter pylori to trospectomycin, pirlimycin (u-57930e), mirincamycin (u-24729a) and n-demethyl clindamycin (u-26767a). european journal of clinical microbiology & infectious diseases. 1993; 12(7): 560-562.
[2]. b. e. gillespie, h. moorehead, p. lunn, h. h. dowlen, d. l. johnson, k. c. lamar, m. j. lewis, s. j. ivey, j. w. hallberg, s. t. chester, and s. p. oliver. efficacy of extended pirlimycin hydrochloride therapy for treatment of environmental streptococcus spp and staphylococcus aureus intramammary infections in lactating dairy cows. veterinary therapeutics. 2002; 3(4): 373-80.

Pirlimycin Upstream-Materialien And Downstream Produkte

Pirlimycin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy